Influence of the enhancers on the bacteriophages adaptation to Pseudomonas aeruginosa clinical strains
Ключові слова:
Pseudomonas aeruginosa, phages, stimulation of bacterial growth, enhancing of phages adaptationАнотація
Introduction. One of the areas of treatment of infectious patients can be considered bacteriophage therapy. It is known that phages have a high specificity, have a different level of lytic activity, and are able to pass into a state of prophage, or adapt to the circulating bacteria strain and acquire the ability to cause their lysis. The purpose of this work was to obtain highly virulent bacteriophages by adapting their moderately sensitive clones to clinical strains of P. aeruginosa. Materials and methods. The object of study was P. aeruginosa 15 strains and 13 freshly isolated clinical strains. For experimental studies used commercial preparations of bacteriophages (Microgen, Perm, Russia)). As enhancers, were used: 1- (3,4-dimethoxybenzyl) -6,7-dimethoxyisoquinoline (0.5 ml), 2.2 ', 2' ', 2' '- (4,8-di (piperidin-1 -yl) pyrimido [5,4-d] pyrimidine-2,6-diyl) bis (azanetriyl) tetraethanol (4 ml), 2- (Phenylmethyl) -1H-benzimidazole (1 ml), which previously showed the ability to synergize to activate microbial growth. Determination of sensitivity to specific bacteriophages was performed by the drip method. The adaptation process included sequential bacteriophage passages in P. aeruginosa cultures, obtaining phage filtrate and release from culture by centrifugation at 5000 rpm. Results and discussion. The total number of strains that became sensitive to phages under the action of adapted phages was 47%, and with enhancers – 67%.In 20.0 % cases, there was a slight growth of secondary colonies (grade "+++") after the 10th passage, and 2 cultures remained resistant to phages, both to the original and adapted by both methods. Conclusion. Thus, by adapting phages to clinical strains of P. aeruginosa, it was possible to increase their lytic activity by 3.5–5 times, which indicates the promise of using this method to obtain highly effective phage preparations and phagolytic vaccines.
Посилання
WHO global antimicrobial resistance strategy. http://www.who.int/drugresistance/WHO_Global_Strategy_Russian.pdf.
Kuznetsova M.V., et al. Carbopenem resistant strains of Pseudomonas aeruginosa in the hospitals of the city of Perm // Klin. microbiol. antimicrobial. chemoter. 2010. Vol. 12. N. 3. P. 246–251.
Nedeljkovic N. S. at al. Pseudomonas aeruginosa serotypes and resistance to antibiotics from wound swabs // Vojnosanit Pregl. 2010. Vol. 12. N.11. P. 999-1000. www. ncbi.nlm.nih.gov/ pubmed/26731974.
Weber-Dabrowska М. et al. Alternative therapies in antibiotic-resistant infection // Advances in Medical Sciences. 2006. Vol. 51. P. 242-244.
Wright С. Н. et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antebiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy// Clinical Otolaryngology. 2009. Vol. 34. Issue 4. P. 349-357.
Aslanov B.I. Justification of the use of bacteriophage to combat Pseudomonas infection in a trauma hospital // Author's abstract dis. med. n St. Petersburg. 2001. 24 P.
Patent application WO2013100792A1. Method for accelerating bacterial biomass growth and attenuating the virulence of bacteria//Martynov A.V, Farber B.S., Farber S.B.
Elkhatib W. F. et al. Evaluation of different microtiter plate-based methods for the quantitative assessment of Staphylococcus aureus biofilms// Future Microbiology. 2011. Vol. 9. N. 6. P. 725-735.
Derkach S.A., Gorodnitskaya N.I., Gabysheva L. Sensitivity to phages in community-acquired strains of Pseudomonas aeruginosa. Phage Adaptation // Materials of the International Scientific and Practical Conference "Theoretical and practical aspects of the development of modern medicine." - June 22-23, 2018.P. 92-96.
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2019 Annals of Mechnikov's Institute
Ця робота ліцензованаІз Зазначенням Авторства – Некомерційна – Без Похідних 3.0 Міжнародна.